Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic and Pharmacodynamic Evaluation from an Expansion Cohort

The aims of this study were to further define the safety of sorafenib and erlotinib, given at their full approved monotherapy doses, and to correlate pharmacokinetic (PK) and pharmacodynamic (PD) markers with clinical outcome. In addition, a novel PD marker based on the real-time measurement of RAF...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Quintela-Fandino, Miguel, Le Tourneau, Christophe, Duran, Ignacio, Chen, Eric X., Wang, Lisa, Tsao, Ming, Bandarchi-Chamkhaleh, Bizhan, Pham, Nhu-Ann, Do, Trevor, MacLean, Martha, Nayyar, Rakesh, Tusche, Michael W., Metser, Ur, Wright, John J., Mak, Tak W., Siu, Lillian L.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2010
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2838726/
https://ncbi.nlm.nih.gov/pubmed/20197396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-09-0868
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items